. 2015 Jul-Aug;19(4):524–528. doi: 10.4103/2230-8210.157859
Copyright: © Indian Journal of Endocrinology and Metabolism
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Table 1.
FDA communication regarding ketoacidosis with SGLT2 inhibitor therapy
